Matrix metalloproteinases and tissue valve degeneration

Journal of Long-Term Effects of Medical Implants

Volumn 11, Issue 3-4, 2001, Pages 221-230

  Bracher, Mona ^a   Simionescu, Dan ^b   Simionescu, Agneta ^b   Davies, Neil ^a   Human, Paul ^a   Zilla, Peter ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Department of Biomedical Research   (Romania)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Bioprosthetic heart valves; Matrix metalloproteinases; Mechanical stress; Proteolytic degradation

Indexed keywords

DETERIORATION; DISEASES; HEART VALVE PROSTHESES; STRESSES;

VALVE DEGENERATION;

TISSUE;

GLUTARALDEHYDE; MATRIX METALLOPROTEINASE;

ANIMAL TISSUE; AORTA VALVE PROSTHESIS; ARTICLE; EXPLANT; HEART VALVE BIOPROSTHESIS; MECHANICAL STRESS; NONHUMAN; PROSTHESIS FAILURE; PROTEIN DEGRADATION; TISSUE DEGENERATION; TISSUE FIXATION;

EID: 0035724787     PISSN: 10506934     EISSN: None     Source Type: Journal    
DOI: 10.1615/jlongtermeffmedimplants.v11.i34.90     Document Type: Article

References (46)

1. Clinical and experimental comparisons establishing the glutaraldehyde treated xenografts as the standard for tissue heart valve replacement
2. The glutaraldehyde stabilized porcine aortic valve
3. Five to eight-year follow-up of patients undergoing porcine heart-valve replacement
4. Founder's Award, 25th Annual Meeting of the Society for Biomaterials, perspectives. Providence, RI, April 28-May 2, 1999. Tissue heart valves: Current challenges and future research perspectives
5. Twelve-year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses
6. A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans Affairs Cooperative Study on Valvular Heart Disease
7. Mechanical loading of bovine pericardium accelerates enzymatic degradation
8. Matrix metalloproteinases
9. The matrix metalloproteinase family
10. Proteinases in cardiovascular aneurysms and rupture: Targets for therapy?
11. The role of matrix metalloproteinases in heart disease
12. Proteinases and matrix degradation
13. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases
14. Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall
15. Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome
16. Increased synthesis of matrix metalloproteinases by aortic smooth muscle cells is implicated in the etiopathogenesis of abdominal aortic aneurysms
17. Smooth muscle cell migration and proliferation is enhanced in abdominal aortic aneurysms
18. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms
19. Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms
20. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm
21. Localization of aortic disease is associated with intrinsic differences in aortic structure
22. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
23. Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis
24. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis
25. Regulation of matrix metalloproteinase gene expression
26. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation
27. Inhibition of extracellular matrix-degrading proteases in pericardial-derived cardiovascular bioprostheses
28. Initiation of mineralization in bioprosthetic heart valves: Studies of alkaline phosphatase activity and its inhibition by AlCl3 or FeCl3 preincubations
29. Alkaline phosphatase activity of glutaraldehyde-treated bovine pericardium used in bioprosthetic cardiac valves
30. Fixation protocols may influence the level of residual matrix metalloproteinase activity in glutaraldehyde fixed porcine aortic tissue
31. Detection of remnant proteolytic activities in unimplanted glutaraldehyde-treated bovine pericardium and explanted cardiac bioprostheses
32. Biochemical pathways of tissue degeneration in bioprosthetic cardiac valves. The role of matrix metalloproteinases
33. Mechanisms of bioprosthetic heart valve failure: Fatigue causes collagen denaturation and glycosaminoglycan loss
34. Macrophage elastase
35. Neutral proteinases of human mononuclear phagocytes. Cellular differentiation markedly alters cell phenotype for serine proteinases, metalloproteinases, and tissue inhibitor of metalloproteinases
36. Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways
37. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators
38. Leukocytes, platelets, and surface microstructure of spontaneously degenerated porcine bioprosthetic valves
39. New aspects of the degeneration of bioprosthetic heart valves after long-term implantation
40. Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves
41. Diamine extension of glutaraldehyde cross-links mitigates bioprosthetic aortic wall calcification in the sheep model
42. Cystatin C deficiency in human atherosclerosis and aortic aneurysms
43. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells
44. The collagenolytic activity of cathepsin K is unique among mammalian proteinases